Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence

BACKGROUNDThis study aimed to evaluate IgG and IgM levels in COVID-19 recurrence. METHODSThe serum antibody levels and clinical data from 73 healthcare workers with SARS-CoV-2 divided into seroconverted (n=51) and non-seroconverted (n=22) groups were assessed. The presence of specific anti-nucleocap...

Full description

Saved in:
Bibliographic Details
Published in:Revista da Sociedade Brasileira de Medicina Tropical 2022-01, Vol.55, p.e01062022-e01062022
Main Authors: Gouvea, Maria da Penha Gomes, Moulaz, Isac Ribeiro, Gouveia, Thayná Martins, Lança, Karen Evelin Monlevade, Lacerda, Bárbara Sthefany de Paula, Thompson, Beatriz Paoli, Polese, Jéssica, Lima, Marina Deorce de, Ribeiro-Rodrigues, Rodrigo, Mill, José Geraldo, Valim, Valéria
Format: Article
Language:English
Subjects:
COVID-19
Humoral Reactivity
Recurrence
SARS-CoV-2
TROPICAL MEDICINE
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUNDThis study aimed to evaluate IgG and IgM levels in COVID-19 recurrence. METHODSThe serum antibody levels and clinical data from 73 healthcare workers with SARS-CoV-2 divided into seroconverted (n=51) and non-seroconverted (n=22) groups were assessed. The presence of specific anti-nucleocapsid (anti-N) IgM and IgG for SARS-CoV-2 was evaluated. IgG antibodies to the SARS-CoV-2 spike receptor-binding domain were used to confirm non-seroconversion in all negative anti-N. RESULTSFour recurrent cases displayed mild symptoms and were non-seroconverted until the recurrence of symptoms. CONCLUSIONSUndetectable anti-nucleocapsid IgM and IgG levels may be correlated with symptomatic COVID-19 recurrence.
ISSN:0037-8682
1678-9849
1678-9849
DOI:10.1590/0037-8682-0106-2022